About Zucara Therapeutics
Zucara Therapeutics is a company based in Vancouver (Canada) founded in 2015. Zucara Therapeutics has raised $50.82 million across 12 funding rounds from investors including Sanofi, National Research Council Canada and Mitacs. The company has 12 employees as of December 31, 2024. Zucara Therapeutics offers products and services including Hypoglycemia Therapeutic. Zucara Therapeutics operates in a competitive market with competitors including Neurocrine, Crinetics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
- Headquarter Vancouver, Canada
- Employees 12 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zucara Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50.82 M (USD)
in 12 rounds
-
Latest Funding Round
$5 M (USD), Series B
Feb 03, 2025
-
Investors
Sanofi
& 12 more
-
Employee Count
12
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zucara Therapeutics
Zucara Therapeutics offers a comprehensive portfolio of products and services, including Hypoglycemia Therapeutic.
Once-daily drug to prevent low blood sugar in diabetes patients.
People of Zucara Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Zucara Therapeutics
Zucara Therapeutics has successfully raised a total of $50.82M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zucara Therapeutics
Zucara Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, National Research Council Canada and Mitacs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Companies developing T1D products are funded through venture philanthropy.
|
Locked | Locked | Locked | |
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Locked | Locked | Locked | |
|
A charitable trust focused on healthcare and research funding.
|
Locked | Locked | Locked |
Investor details for Zucara Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zucara Therapeutics
Investment portfolio details for Zucara Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zucara Therapeutics
Detailed financials for Zucara Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zucara Therapeutics Comparisons
Peer comparison for Zucara Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zucara Therapeutics
Zucara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are provided for treating chronic inflammatory diseases.
|
Detailed competitors of Zucara Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zucara Therapeutics
Complete news archive for Zucara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zucara Therapeutics
Zucara Therapeutics was founded in 2015.
Zucara Therapeutics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Zucara Therapeutics is a funded company, having raised a total of $50.82M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Zucara Therapeutics is 12.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing a novel drug for the treatment of hypoglycemia associated with insulin therapy. Their lead candidate PRL-2903 works via the chronic receptor antagonism through which they block somatostatin type 2 (SSTR2) receptors on α-cells in the pancreas.
Zucara Therapeutics's top competitors include Crinetics, Neurocrine and MBX Biosciences.
Zucara Therapeutics offers Hypoglycemia Therapeutic.
Zucara Therapeutics has 13 investors. Key investors include Sanofi, National Research Council Canada, Mitacs, Perceptive Advisors, and Canadian Space Agency.